Holen Sie sich die Stockscreener-App
24.89
0.36%
-0.09
Vorhandelsmarkt:
25.00
0.11
+0.44%
Schlusskurs vom Vortag:
$24.98
Offen:
$24.98
24-Stunden-Volumen:
3.22M
Relative Volume:
0.89
Marktkapitalisierung:
$4.60B
Einnahmen:
$637.78M
Nettoeinkommen (Verlust:
$239.40M
KGV:
20.90
EPS:
1.1909
Netto-Cashflow:
$307.21M
1W Leistung:
+0.93%
1M Leistung:
+9.31%
6M Leistung:
-62.18%
1J Leistung:
-58.05%
1-Tages-Spanne:
$24.55
$25.67
1-Wochen-Bereich:
$23.40
$25.67
52-Wochen-Spanne:
$20.55
$76.51
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, BTSG, TEM, HQY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
24.89 | 4.60B | 637.78M | 239.40M | 307.21M | 1.1909 |
VEEV
Veeva Systems Inc
|
170.22 | 27.80B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
53.54 | 10.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
55.81 | 10.01B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
82.18 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Truist | Buy → Hold |
| 2026-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2026-02-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2026-02-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-01-08 | Hochstufung | Truist | Hold → Buy |
| 2025-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-10-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Herabstufung | Goldman | Neutral → Sell |
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Is Doximity, Inc. (DOCS) A Good Stock To Buy Now? - Insider Monkey
Is Doximity (DOCS) a Good Stock to Buy? Bullish Thesis Breakdown - HarianBasis.co
Doximity earnings up next: Can guidance ease valuation pressure? By Investing.com - Investing.com Nigeria
Move Over Doximity — There’s a New Social Network for Doctors - MedCity News
Paul Jorgensen of Doximity Pleads Guilty in $2.5M Insider Trading Case - hannahhowell.com
Assessing Doximity (DOCS) Valuation After Recent Share Price Volatility - Yahoo Finance
JPMorgan Small Cap Equity Fund's Doximity Inc(DOCS) Holding History - GuruFocus
DOCS SEC FilingsDoximity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Should Doximity’s CFO Transition Before Earnings Require Action From Doximity (DOCS) Investors? - simplywall.st
Vanguard reports 6.79M Doximity shares; Schedule 13G shows 5.07% (DOCS) - Stock Titan
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack (NYSE:DOCS) - Seeking Alpha
Doximity Stock at $25: Priced for Decline or Positioned for a Double-Digit Rebound? - TIKR.com
Is It Too Late To Consider Buying Doximity, Inc. (NYSE:DOCS)? - 富途牛牛
Doximity drops as guidance trails consensus - MSN
Doximity (DOCS) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Evercore Maintains Doximity(DOCS.US) With Hold Rating, Maintains Target Price $25 - Moomoo
Doximity CFO resigns; interim finance head continues - msn.com
Doximity, Inc. (DOCS) Stock Analysis: A Look at Its 57% Potential Upside and Strong Buy Sentiment - DirectorsTalk Interviews
Doximity CFO Exit Puts Focus On Finance Stability And Capital Choices - Sahm
Doximity reaches $31M settlement in securities litigation lawsuit - MSN
Evercore ISI Group Maintains Doximity (DOCS) Outperform Recommendation - MSN
Doximity (DOCS) stock dips while market gains: Key facts - MSN
Evercore ISI Group downgrades Doximity (DOCS) - MSN
Victory Sustainable World Fund's Doximity Inc(DOCS) Holding History - GuruFocus
Doximity to Release Fiscal 2026 Fourth Quarter and Full Year Results on May 13, 2026 - The Joplin Globe
Raymond James reiterates Strong Buy on Doximity stock amid OpenAI launch By Investing.com - Investing.com India
VY(R) JPMorgan Small Cap Core Equity Portfolio's Doximity Inc(DOCS) Holding History - GuruFocus
Raymond James reiterates Strong Buy on Doximity stock amid OpenAI launch - Investing.com Australia
Wall Street Analysts Think Doximity (DOCS) Is a Good Investment: Is It? - Yahoo Finance
Will Enterprise Deals & MedTech Momentum Fuel OPRX's Growth Engine? - TradingView
Doximity (NYSE:DOCS) Stock Rating Upgraded by Zacks Research - MarketBeat
Is Doximity (DOCS) stock stable under market conditions | Doximity posts 1.2% EPS beat, solid Q1 revenueBest Pick - Xã Thanh Hà
DOCS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform - TradingView
Truist Securities downgrades Doximity (DOCS) - MSN
Doximity (DOCS) falls more steeply than broader market: What investors need to know - MSN
Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
BofA Cuts PT on Doximity, Inc. (DOCS) to $47 From $56 - Insider Monkey
Doximity (NYSE:DOCS) Shares Gap DownTime to Sell? - MarketBeat
Doximity stock holds Strong Buy at Raymond James after CFO exit By Investing.com - Investing.com South Africa
Doximity stock holds Strong Buy at Raymond James after CFO exit - Investing.com Australia
Leerink raises Doximity stock price target to $34 on valuation By Investing.com - Investing.com South Africa
Doximity (DOCS) Faces Downgrade and Adjusted Growth Outlook - GuruFocus
Leerink raises Doximity stock price target to $34 on valuation - Investing.com UK
This Qorvo Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
Truist Financial Maintains Doximity(DOCS.US) With Hold Rating, Maintains Target Price $29 - Moomoo
Robinhood To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Doximity Inc : Leerink Partners Cuts Target P - Moomoo
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
7.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):